Meinolf Karthaus

Medicine · Health Sciences

47h-index8.2kcitations324works2.62yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(98), Neutropenia and Cancer Infections(76), Antifungal resistance and susceptibility(60), Fungal Infections and Studies(52), Gastric Cancer Management and Outcomes(37)

Publications319 total

Disseminated <i>Lomentospora prolificans</i> infection in a patient with neutropenia treated with ipilimumab and nivolumab
BMJ Case Reports·2026Open Access
Voriconazole (VCZ) therapeutic drug monitoring (TDM) for prophylaxis and treatment of invasive fungal diseases in hematology patients – daily clinical practice and evidence from clinical trials
Blood·2025Open Access
Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216)
British Journal of Cancer·2025Open Access
772P Perioperative atezolizumab with or without the immunomodulatory IMM-101 in patients (pts) with MSI-high (MSI-H) or MMR-deficient (dMMR) stage III colorectal cancer (CRC) ineligible for oxaliplatin-based chemotherapy: The randomised phase II ANTONIO-study (AIO-KRK-0220)
Annals of Oncology·2025
2801O Personalizing antiemetic prophylaxis for patients at high emetic risk: Results from the MyRisk Trial
Annals of Oncology·2025
2251P Immune features of the tumor microenvironment are mirrored in PBMCs and predict second-line outcome in advanced pancreatic cancer: Insights from the PREDICT trial
Annals of Oncology·2025
An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial
Molecular Cancer·2025· 1 citedOpen Access
Prognostic and predictive impact of the baseline systemic proteome in patients with <i>RAS</i> wild-type metastatic colorectal cancer: Analysis from the randomized phase II PanaMa (AIO KRK0212) trial.
Journal of Clinical Oncology·2025
A PBMC and machine learning based biomarker signature to predict second line chemotherapy success in advanced PDAC: Translational data of the PREDICT trial—A prospective, multicenter, trial of the AIO Pancreatic Cancer Group (AIO-PAK-0216).
Journal of Clinical Oncology·2025
2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignancies
The Lancet Regional Health - Europe·2025· 15 citedOpen Access
Second-line therapy with Nal-IRI/5-FU/FA after failure of gemcitabine/nab-paclitaxel in advanced pancreatic cancer (PC): Predictive role of 1st-line therapy (PREDICT) and impact of quality of life (QoL).
Journal of Clinical Oncology·2025
Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase 2 trial
EClinicalMedicine·2024· 2 citedOpen Access
Evaluation of circulating tumor <scp>DNA</scp> as a prognostic and predictive biomarker in <i>BRAF</i> <scp>V600E</scp> mutated colorectal cancer—results from the <scp>FIRE</scp> ‐4.5 study
Molecular Oncology·2024· 6 citedOpen Access
40 Years of Preventing Fungal Infections in Hematological Malignancies - Lessons Learned from Clinical Trials with 20,753 Patients
Blood·2024Open Access
Author response for "Evaluation of circulating tumor &lt;scp&gt;DNA&lt;/scp&gt; as a prognostic and predictive biomarker in &lt;i&gt;BRAF&lt;/i&gt;&lt;scp&gt;V600E&lt;/scp&gt; mutated colorectal cancer—results from the &lt;scp&gt;FIRE&lt;/scp&gt;‐4.5 study"
2024
581P mRNA profiling as a biomarker of prognosis and response to first-line treatment in metastatic colorectal cancer: Discovery and validation of a gene expression signature in three randomized trials
Annals of Oncology·2024Open Access
Functional status and quality of life in older patients with advanced esophageal squamous cell cancer receiving second-line nivolumab ± ipilimumab therapy: A post hoc analysis of the phase 2, multicenter RAMONA study
Journal of Geriatric Oncology·2024· 1 citedOpen Access
Subgroup analyses from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial
BMC Cancer·2024· 2 citedOpen Access
Author response for "Evaluation of circulating tumor &lt;scp&gt;DNA&lt;/scp&gt; as a prognostic and predictive biomarker in &lt;i&gt;BRAF&lt;/i&gt;&lt;scp&gt;V600E&lt;/scp&gt; mutated colorectal cancer—results from the &lt;scp&gt;FIRE&lt;/scp&gt;‐4.5 study"
2024
Dermatology-related quality-of-life outcomes in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX + Pmab induction: a prespecified secondary analysis of the phase II randomized PanaMa (AIO KRK 0212) trial
ESMO Open·2024· 4 citedOpen Access
page 1 of 16Next →

Frequent Co-authors

Oliver A. Cornely(20), Dieter Buchheidt(20), Markus Ruhnke(17), Georg Maschmeyer(15), Andrew J. Ullmann(13), Olaf Penack(13), Werner Heinz(9), Angelika Böhme(7), Gerda Silling(7), Florian Weißinger(6), Arnold Ganser(6), J. Ritter(5), Michael Sandherr(5), Jörg Janne Vehreschild(5), Maximilian Christopeit(5), Hermann Einsele(5), Maria J. G. T. Vehreschild(5), Stefan Schwartz(5), Martin Schmidt‐Hieber(5), William Krüger(4)